Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) EBT (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EBT for 5 consecutive years, with -$10.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 49.66% to -$10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.8 million through Dec 2025, up 12.2% year-over-year, with the annual reading at -$62.8 million for FY2025, 12.2% up from the prior year.
  • EBT for Q4 2025 was -$10.2 million at Werewolf Therapeutics, up from -$16.4 million in the prior quarter.
  • The five-year high for EBT was -$5.1 million in Q2 2023, with the low at -$20.3 million in Q4 2024.
  • Average EBT over 5 years is -$13.7 million, with a median of -$14.3 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 65.9% in 2023, then plummeted 260.91% in 2024.
  • Over 5 years, EBT stood at -$17.9 million in 2021, then surged by 33.03% to -$12.0 million in 2022, then increased by 0.02% to -$12.0 million in 2023, then tumbled by 69.26% to -$20.3 million in 2024, then soared by 49.66% to -$10.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$10.2 million, -$16.4 million, and -$18.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.